Jupiter Neurosciences Announces Pricing of $2.0 Million Registered Direct Offering
Globe Newswire (Fri, 21-Aug 12:20 PM ET)
Market Chameleon (Fri, 21-Aug 3:28 AM ET)
Globe Newswire (Fri, 21-Aug 7:00 AM ET)
Jupiter Neurosciences, Inc. Announces Reverse Stock Split
Globe Newswire (Wed, 5-Aug 8:00 AM ET)
Market Chameleon (Tue, 21-Jul 5:54 AM ET)
Globe Newswire (Tue, 21-Jul 7:13 AM ET)
Globe Newswire (Tue, 21-Jul 7:00 AM ET)
Jupiter Neurosciences Strengthens Board with Appointment of Dr. Tomas J. Philipson
Globe Newswire (Tue, 7-Jul 8:58 AM ET)
Market Chameleon (Wed, 20-May 5:51 AM ET)
Jupiter Neurosciences Inc is a clinical-stage research and development company focused on developing treatments for neuroinflammation through the resveratrol platform. Its platform product, JOTROL, is an enhanced oral formulation of resveratrol, which has many potential indications. In the larger disease areas, which are targeting Parkinson's Disease. The group is presently in the process of conducting a Phase IIa clinical trial in Parkinson's Disease. The company operates through two reportable segments: premium nutritional supplements and pharmaceutical operations focused on drug candidates for CNS and rare orphan diseases. It generates the majority of its revenue from Premium Nutritional Supplements, which includes commercialization and sales of the Company's Nugevia product line.
Jupiter Neurosciences trades on the NASDAQ stock market under the symbol JUNS.
As of September 28, 2026, JUNS stock price declined to $2.51 with 50,068 million shares trading.
JUNS has a beta of 0.44, meaning it tends to be less sensitive to market movements. JUNS has a correlation of 0.00 to the broad based SPY ETF.
JUNS has a market cap of $3.31 million. This is considered a Sub-Micro Cap stock.
Last quarter Jupiter Neurosciences reported $24,245 in Revenue and -$4.08 earnings per share. This fell short of revenue expectation by $-375,755 and missed earnings estimates by -$.33.
The top ETF exchange traded funds that JUNS belongs to (by Net Assets): VXF.
JUNS has underperformed the market in the last year with a price return of -97.6% while the SPY ETF gained +17.5%. JUNS has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -85.9% and -17.7%, respectively, while the SPY returned +4.5% and +0.4%, respectively.
JUNS support price is $2.43 and resistance is $2.91 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that JUNS shares will trade within this expected range on the day.
